转移性肾癌索拉非尼治疗失败后联合间歇化疗的初步经验(附10例报告)  

Initial experience of the combination of sorafenib and intermittent chemotherapy for metastatic renal cell carcinoma after failure of single agent sorafenib(Report of ten cases)

作　　者：喻彬[1,2] 蔡宏宙[1,2] 徐子程[1,2] 须霆[1,2] 邹青[1,2] 

机构地区：[1]南京医科大学附属肿瘤医院 [2]江苏省肿瘤防治研究所泌尿外科,南京210009

出　　处：《临床泌尿外科杂志》2015年第7期604-606,共3页Journal of Clinical Urology

基　　金：南京市科技计划项目(编号201201087)

摘　　要：目的：评价转移性肾癌索拉非尼治疗失败后联合吉西他滨＋替吉奥化疗的疗效及毒副作用。方法：对10例索拉非尼治疗失败的转移性肾癌患者联合间歇化疗。化疗方案为吉西他滨1.0g/m2×1、8d＋替吉奥0.5bid×1~14d,每21天为1个周期,首轮4周期后化疗间歇性重复进行。化疗同时继续口服索拉非尼400mg bid,直至治疗失败或患者不能耐受。观察治疗效果及毒副作用。结果：全部10例患者总体反应率（ORR）100%,中位无疾病进展时间（PFS）11个月,中位总生存时间（OS）20个月。毒副反应主要为Ⅱ~Ⅲ度骨髓抑制和消化道反应。结论：转移性肾癌酪氨酸激酶抑制剂（TKI）治疗失败后联合吉西他滨＋替吉奥间歇化疗安全有效,值得进一步探索。Objective：To investigate the efficacy and safety of sorafenib combined with gemeitabine plus S-1 for patients with metastatic renal cell carcinoma after failure of single agent sorafenib. Method：Ten cases with meta- static renal cell carcinoma were eligible for this study. All the patients received gemcitabine （1 g/m2^） on the first and eighth day, and S-1 （0.5 bid） once a day for 14 days, every three weeks as a cycle. Chemotherapy was inter- mittent after four cycles were performed. At the same time, patients received oral sorafenib （400 rag, bid） until the disease progression or patients intolerance. Result： Overall response rate （ORR） was 100~, and median pro- gression free survival （PFS） was 11 months. Median overall survival （OS） was 20 months. The most common toxic side effects included Ⅱ-Ⅲ myelosuppression and gastrointestinal reaction. Conclusion： The combination of sorafenib, gemcitabine and S-1 is effective and safe for patients with metastatic renal cell carcinoma after failure of tyrosine kinase inhibitor （TKI）, and it＇s worthy of further investigation.

关 键 词：肾癌 化学治疗 索拉非尼 

分 类 号：R737.11[医药卫生—肿瘤]